Markets:

Overview

News

Currencies

International

Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

5.349 +0.149 (+2.87%)

Streaming Delayed Price Updated: 12:48 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options

June 29, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics's Return On Capital Employed Insights ↗

June 10, 2022

According to Benzinga Pro, during Q1, AbCellera Biologics (NASDAQ:ABCL) earned $168.57 million, a 181.2% increase from the preceding quarter. AbCellera Biologics also posted a total of $316.58 million...

Via Benzinga

Cramer Shares His Thoughts On Stem, Marvell Technology And More ↗

May 17, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology Inc (NASDAQ: MRVL) is the "best when it comes to 5G, the best in high-performance computing.

Via Benzinga

What 4 Analyst Ratings Have To Say About AbCellera Biologics ↗

May 11, 2022

Over the past 3 months, 4 analysts have published their opinion on AbCellera Biologics (NASDAQ:ABCL) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Recap: AbCellera Biologics Q1 Earnings ↗

May 10, 2022

AbCellera Biologics (NASDAQ:ABCL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Sunday Memo - Dec. 5 ↗

December 05, 2021

The market rout was worldwide last week.

Via Talk Markets

AbCellera Reports Q1 2022 Business Results

May 10, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration

May 03, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022

April 26, 2022

From AbCellera Biologics Inc.

Via Business Wire

3 Biotech Stocks Under $10 to Add to Your Buy List ↗

April 26, 2022

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk.

Via InvestorPlace

AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022

April 12, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Presents Data on T Cell Engager Platform at AACR 2022

April 08, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Reports Full Year 2021 Business Results

February 24, 2022

From AbCellera Biologics Inc.

Via Business Wire

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

February 23, 2022

From AbCellera Biologics Inc.

Via Business Wire

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19 ↗

February 14, 2022

The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized...

Via Benzinga

AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19

February 11, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022

February 11, 2022

From AbCellera Biologics Inc.

Via Business Wire

Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments

February 10, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

January 27, 2022

From AbCellera

Via Business Wire

Top Biotech Stocks: Trading Opportunities For Next Week ↗

December 19, 2021

A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns.

Via Talk Markets

AbCellera Announces Changes to Its Board of Directors

December 07, 2021

From AbCellera Biologics Inc.

Via Business Wire

Futures Rebound From Friday Rout As Omicron Fears Ease ↗

December 06, 2021

S&P futures and European stocks rebounded from Friday’s selloff while Asian shares fell, as investors took comfort in reports from South Africa which said initial data doesn’t show a surge of...

Via Talk Markets

Topics Stocks

Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns ↗

December 06, 2021

The FDA has expanded the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) bamlanivimab and etesevimab administered together to include...

Via Benzinga

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

December 03, 2021

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

December 02, 2021

From AbCellera Biologics Inc.

Via Business Wire

Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail? ↗

November 29, 2021

Smaller companies are working on next-generation approaches to Covid treatment.

Via Investor's Business Daily

These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19 ↗

November 29, 2021

Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

Friday Markets Coverage ↗

November 19, 2021

Today markets are suffering alongside Austria which locked down against Covid-19 again.

Via Talk Markets

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.